Horizon Pharma (HZNP) Misses Q1 EPS by 4c, Raises FY Revenue Guidance

Horizon Pharma (NASDAQ: HZNP) reported Q1 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $223.9 million versus the consensus estimate of $233.37 million.

GUIDANCE:

Horizon Pharma sees FY2018 revenue of $1.17-1.2 billion, versus the consensus of $1.15 billion.

• Full-year 2018 adjusted EBITDA is now expected to be $390 million to $415 million, an increase from the previous range of $370 million to $395 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Movano (MOVE) Misses Q2 EPS by 195c